ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2616

Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort

Mirette Habib1, Sara Jaafar 1, Annie Park 1, Suiyuan Huang 1, Wen Ye 1, Vivek Nagaraja 1, Eric White 1, Kevin Flaherty 2 and Dinesh Khanna 3, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 3Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Computed tomography (CT), forced vital capacity and systemic sclerosis, interstitial lung disease, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as % predicted) is a valid outcome measure to assess lung function in patients with ILD. Our objective was to determine whether varying trajectories of FVC in patients with SSc-ILD were associated with different phenotypes of disease.

Methods: Patient data was collected from the electronic medical records of SSc  patients seen in the senior author’s clinic. SSc patients who completed Chest Computed Tomography (CTs), to evaluate presence of ILD, and had at least 3 FVC measurements that were at least 3 months apart were included in the analysis. A latent class growth analysis model, PROC TRAJ, was used to identify heterogeneous groups among SSc-ILD patients according to their FVC trajectories over time.T-test and Chi-square test were used to compare baseline characteristics among the identified subpopulations.

Results: Out of 484 SSc patients in our cohort, 293 had evidence of ILD on a chest CT of which 86% of which were high resolution CTs (HRCTS). Of the 293 patients with ILD,188 also had at least 3 FVC measurements performed at least 3 months apart. The median [IQR] for follow-up was 42 [25] months and estimated change in FVC among all patients was –2.87% in 100 months. We identified 5 subpopulations with distinct trajectories of FVC% in SSc-ILD patients (group mean trajectories as shown in Figure 1). Groups 1-3 had abnormal baseline FVC% (mean < 80%) whereas Groups 4 and 5 had normal mean baseline FVC% (Table 1). The majority of our cohort fell into Group 2 (27%), Group 3 (22%), or Group 4 (30%). Group 1 had the lowest estimated FVC% at baseline and greatest decline in estimated FVC%, younger age, higher prevalence of males and African-Americans, and had higher deaths compared to the other groups; the median disease duration was similar in the 5 groups (Table 1) at baseline. Significant differences were found in the patterns of ILD on chest CTs, with Usual Interstitial Pneumonitis (UIP) being more prevalent in low FVC Groups (1 and 2).

Conclusion: Our results suggest 5 distinct groups of patients with SSc-ILD with respect to change in FVC over time. Ongoing work will quantify degree of ILD on chest CTs and the impact of immunosuppressive therapy on long term outcomes in this cohort.

Figure 1: Trajectory Groups for SSc-ILD

Table 1: Baseline Demographics by Trajectory Groups for SSc-ILD


Disclosure: M. Habib, None; S. Jaafar, None; A. Park, None; S. Huang, None; W. Ye, None; V. Nagaraja, None; E. White, None; K. Flaherty, Bellepheron, 5, Blade, 5, Boehringer Ingelheim, 5, Roche/Genentech, 5, Veracyte, 5; D. Khanna, Acceleron, 5, 8, Acceleron Pharma, 5, Actelion, 5, 8, Actelion Pharmaceuticals, 5, Astra Zeneca, 5, Bayer, 2, 5, 8, Behring, 5, Blade, 5, Blade Therapeutics, 5, 8, Blade therapeutics, 5, BMS, 2, 5, 8, Boehringer Ingelham, 5, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 5, Celgene, 5, 8, ChemomAB, 5, ChemomAb, 5, CiviBioPharma, Inc., 3, Corbus, 5, Corobus, 5, Corpus, 5, CSL Behring, 5, 8, Curizon, 5, Curzion, 5, Cytori, 5, 8, Eicos, 4, Eicos Sciences, 4, Eicos Sciences, Inc, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc, 1, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc., 1, Eicos, Inc, 4, Eicos, Inc., 5, 8, Eicos, INC., 4, Galapagos, 5, Genentech, 5, Genentech/Roche, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 2, 5, Mitsubishi Tanabe Pharma, 5, Mitsubishi Tanabe Pharma Dev America, 5, Mitsubishi Tanabe Pharma Development America, 5, Mitsubishi Tanabi, 5, NIH K24 and R01, 2, NIH / NIAMS K24 AR-063120, 2, NIH/NIAMS R01& K24, 2, Pfizer, 2, 5, Sanofi, 5, Sanofi Aventis, 5, Sanofi-Aventis, 5, 8, Sanofi-Aventis/Genzyme, 5, UCB, 5, UCB Pharma, 5.

To cite this abstract in AMA style:

Habib M, Jaafar S, Park A, Huang S, Ye W, Nagaraja V, White E, Flaherty K, Khanna D. Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/forced-vital-capacity-trajectories-for-systemic-sclerosis-associated-interstitial-lung-disease-analysis-from-the-university-of-michigan-scleroderma-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/forced-vital-capacity-trajectories-for-systemic-sclerosis-associated-interstitial-lung-disease-analysis-from-the-university-of-michigan-scleroderma-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology